The company said, “Cytek Biosciences (CTKB) expects total revenue for the year ended December 31, 2025 to be in the range of $204 million to $212 million, representing growth of 2% to 6% over the year ended December 31, 2024, assuming no change in currency exchange rates.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences price target raised to $5.25 from $4.50 at Goldman Sachs
- Cytek Biosciences downgraded to Sell from Buy at Goldman Sachs
- Big banks report Q4 beats, QXO proposes to buy Beacon: Morning Buzz
- Morning Movers: Wells Fargo and Citi gain following Q4 earnings
- Cytek Biosciences sees Q4 revenue $57M-$58M, consensus $61.49M